IncyteCARES (Connecting to Access, Reimbursement, Education and Support) provides a single point of contact through a registered nurse who has received OCN® certification to assist healthcare providers in obtaining access to Jakafi for their eligible patients and to connect those patients with continuing support and resources.
Information About Independent Third-Party Organizations‡ That May Be Able To Assist With:
OCN is a registered trademark of Oncology Nursing Certification Corporation.
*Amount of savings for the purchase of Jakafi will not exceed $11,977 per month and $25,000 per year. Uninsured, cash-paying patients are not eligible. Not valid for patients insured through Medicare Part D, Medicare Advantage, Medicaid, and TRICARE or any state medical or pharmaceutical assistance program. Valid prescription for Jakafi for an FDA-approved indication is required. Please see full criteria for eligibility below or call IncyteCARES. Update effective as of September 30, 2019.
†Terms, conditions, and additional eligibility criteria apply. Valid prescription for Jakafi for an FDA-approved indication is required. Patients insured through Medicare, Medicaid, and TRICARE are not eligible. Free product is offered to eligible patients without any purchase contingency or other obligation.
‡Some foundations or organizations may receive or have received donations from Incyte Corporation.
You may enroll your eligible patients online. INCYTECARES ONLINE ENROLLMENT FORM
Connect with IncyteCARES today! Visit IncyteCARES.com or call 1-855-4-Jakafi (1-855-452-5234), Monday through Friday, 8 AM–8 PM ET.
You may enroll your eligible patients online. INCYTECARESONLINE ENROLLMENT FORM
Indications and Usage
Jakafi is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high‐risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid‐refractory acute graft‐versus‐host disease (GVHD) in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
You are now leaving the Jakafi.com website.
You are now leaving the Jakafi.com website. This link will take you to a site that is not owned or maintained by Incyte Corporation, and Incyte is not responsible for the information contained on third party sites.